4D Molecular Therapeutics, Inc.
FDMTNasdaq
$10.99
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↑ +158.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$748.0M
Enterprise Value
$357.1M
P/E
—
P/S
8.5
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$88.2M
Net Income (TTM)
-$160.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-203.5%
Net Margin
-182.3%
ROE
-35.6%
ROIC
-232.7%
Debt / Equity
—
Net Cash
$390.9M
Return 1Y
+152.1%
Company profile
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.
- CEO
- David H. Kirn
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- California
- Website
- 4dmoleculartherapeutics.com
Management & directors
- Kirn DavidSee Remarks
- Bizily ScottChief Legal Officer
- Gupta AshooVP, Finance and Controller
Roles derived from SEC Form 4 filings.
Earnings
FDMT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.0M↑ +21664.3%
Diluted EPS-$1.01↑ +17.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $18.0M | $3.1M | $20.7M | $37,000.00 | $85.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$56.7M | -$71.3M | -$110.0M | -$112.9M | -$187.8M | -$159.5M |
| Net income | -$56.7M | -$71.3M | -$107.5M | -$100.8M | -$160.9M | -$140.1M |
| Diluted EPS | — | -$2.57 | -$3.32 | -$2.58 | -$2.98 | -$2.42 |
| Operating cash flow | -$50.9M | -$69.1M | -$86.7M | -$75.8M | -$134.6M | -$109.1M |
| Free cash flow | -$51.9M | -$78.2M | -$98.2M | -$78.6M | -$138.4M | -$109.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -416.3% | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Net margin | -416.5% | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5,000.00 | $3,000.00 | $1,000.00 | $14,000.00 | $15,000.00 | $90,000.00 | $85.1M | $3.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$42.5M | -$51.1M | -$56.1M | -$53.6M | -$59.5M | -$61.2M | $14.7M | -$73.6M |
| Net income | -$35.0M | -$43.8M | -$49.7M | -$48.0M | -$54.7M | -$56.9M | $19.4M | -$68.8M |
| Diluted EPS | -$0.63 | -$0.79 | -$0.90 | -$0.86 | -$0.98 | -$1.01 | $0.43 | -$1.01 |
| Operating cash flow | -$30.2M | -$29.4M | -$45.9M | -$47.8M | -$43.4M | -$46.5M | $28.6M | -$68.1M |
| Free cash flow | -$30.6M | -$31.2M | -$46.8M | -$48.4M | -$43.4M | -$46.6M | $28.5M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -849120.0% | -1704400.0% | -5611700.0% | -383007.1% | -396373.3% | -67983.3% | 17.3% | -2416.1% |
| Net margin | -699060.0% | -1461433.3% | -4967100.0% | -342657.1% | -364386.7% | -63195.6% | 22.8% | -2256.6% |
Company news
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Kirn David· See Remarks | Sale | 15,283 | $12.01 | $183,559.53 | filing |
| 2026-07-10 | Kirn David· See Remarks | Sale | 442 | $12.84 | $5,673.29 | filing |
| 2026-07-09 | Kirn David· See Remarks | Sale | 42,608 | $12.87 | $548,177.48 | filing |
| 2026-06-30 | Bizily Scott· Chief Legal Officer | Sale | 6,566 | $14.00 | $91,924.00 | filing |
| 2026-06-30 | Bizily Scott· Chief Legal Officer | Option exercise | 5,752 | $6.49 | $37,330.48 | filing |
| 2026-06-30 | Bizily Scott· Chief Legal Officer | Option exercise | 814 | $4.14 | $3,369.96 | filing |
| 2026-06-23 | Bizily Scott· Chief Legal Officer | Sale | 9,810 | $12.00 | $117,720.00 | filing |
| 2026-06-23 | Bizily Scott· Chief Legal Officer | Option exercise | 9,810 | $4.14 | $40,613.40 | filing |
| 2026-06-22 | Kirn David· See Remarks | Sale | 114,746 | $10.47 | $1.2M | filing |
| 2026-06-01 | Kirn David· See Remarks | Sale | 1,922 | $10.02 | $19,257.86 | filing |
| 2026-06-01 | Kirn David· See Remarks | Sale | 1,922 | $10.02 | $19,257.86 | filing |
| 2026-03-20 | Gupta Ashoo· VP, Finance and Controller | Sale | 310 | $8.61 | $2,669.10 | filing |
| 2026-03-20 | Gupta Ashoo· VP, Finance and Controller | Sale | 80 | $8.61 | $688.80 | filing |
| 2026-03-20 | Gupta Ashoo· VP, Finance and Controller | Option exercise | 221 | — | — | filing |
| 2026-03-20 | Gupta Ashoo· VP, Finance and Controller | Option exercise | 865 | — | — | filing |
| 2025-12-20 | Gupta Ashoo· VP, Finance and Controller | Sale | 310 | $8.68 | $2,690.80 | filing |
| 2025-12-20 | Gupta Ashoo· VP, Finance and Controller | Sale | 79 | $8.68 | $685.72 | filing |
| 2025-12-20 | Gupta Ashoo· VP, Finance and Controller | Option exercise | 866 | — | — | filing |
| 2025-12-20 | Gupta Ashoo· VP, Finance and Controller | Option exercise | 220 | — | — | filing |
| 2025-12-16 | Bizily Scott· Chief Legal Officer | Sale | 1,635 | $10.90 | $17,821.50 | filing |
| 2025-12-16 | Bizily Scott· Chief Legal Officer | Option exercise | 1,635 | $4.14 | $6,768.90 | filing |
| 2025-12-12 | THEUER CHARLES | Option exercise | 9,333 | $1.14 | $10,639.62 | filing |
| 2025-11-17 | Bizily Scott· Chief Legal Officer | Sale | 1,635 | $10.59 | $17,314.65 | filing |
| 2025-11-17 | Bizily Scott· Chief Legal Officer | Option exercise | 1,635 | $4.14 | $6,768.90 | filing |
| 2025-10-24 | Bizily Scott· Chief Legal Officer | Sale | 2,678 | $12.00 | $32,136.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.